Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens
In this observational cohort study, the objective was to compare low-density lipoprotein (LDL) cholesterol dynamics in people with HIV (PWH) who switched to a regimen containing doravirine (DOR), rilpivirine, dolutegravir, or bictegravir and were naïve to the studied drugs. Generalized additive mixed models were used to examine LDL cholesterol dynamics. LDL cholesterol was measured in 2381 PWH: during the first two years, DOR had the greatest lowering effect and showed the most favorable lipid outcome.
Authors
- Camilla Muccini (ORCID: https://orcid.org/0000-0002-0900-5639)
- Riccardo Lolatto (ORCID: https://orcid.org/0000-0002-2447-6498)
- Silvia Nozza
- Monica Guffanti
- Emanuela Messina (ORCID: https://orcid.org/0000-0001-8093-015X)
- Hamid Hasson (ORCID: https://orcid.org/0000-0002-1938-7335)
- Laura Galli (ORCID: https://orcid.org/0000-0001-8046-0290)
- Vincenzo Spagnuolo (ORCID: https://orcid.org/0000-0002-9656-7217)
- Nicola Gianotti (ORCID: https://orcid.org/0000-0002-7182-5080)
- Sara Diotallevi (ORCID: https://orcid.org/0009-0003-2559-7042)
- Diana Canetti
- Antonella Castagna
- Michele Bellomo
Institutions
- Vita-Salute San Raffaele University (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- AIDS
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1097/qad.0000000000004072
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00